Dec. 26 at 6:29 AM
$PCSC
"We founded PCSC to partner with transformational life sciences companies, and Freenome represents exactly the type of business we set out to support," said Adam Stone, Chief Investment Officer of Perceptive Advisors and CEO of PCSC. "Freenome has built a leading platform, assembled top-tier strategic partners, and demonstrated a clear path toward making blood-based cancer screening broadly accessible. We are thrilled to partner with the Freenome team and to support the company through its next stage of growth.”